JP2014521658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521658A5 JP2014521658A5 JP2014523092A JP2014523092A JP2014521658A5 JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5 JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- laquinimod
- day
- glatiramer acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512808P | 2011-07-28 | 2011-07-28 | |
| US61/512,808 | 2011-07-28 | ||
| PCT/US2012/048684 WO2013016684A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Division JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521658A JP2014521658A (ja) | 2014-08-28 |
| JP2014521658A5 true JP2014521658A5 (enExample) | 2015-09-17 |
Family
ID=47597714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523092A Withdrawn JP2014521658A (ja) | 2011-07-28 | 2012-07-27 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130029916A1 (enExample) |
| EP (1) | EP2736335A4 (enExample) |
| JP (2) | JP2014521658A (enExample) |
| KR (1) | KR20140054166A (enExample) |
| CN (2) | CN103781354A (enExample) |
| AU (2) | AU2012286699A1 (enExample) |
| BR (1) | BR112014002095A2 (enExample) |
| CA (1) | CA2843433A1 (enExample) |
| CL (2) | CL2014000209A1 (enExample) |
| EA (1) | EA201490377A1 (enExample) |
| HK (2) | HK1198279A1 (enExample) |
| IL (1) | IL251397A0 (enExample) |
| IN (1) | IN2014MN00333A (enExample) |
| MX (1) | MX2014001050A (enExample) |
| PE (1) | PE20142319A1 (enExample) |
| SG (1) | SG10201606191PA (enExample) |
| UY (1) | UY34358A (enExample) |
| WO (1) | WO2013016684A1 (enExample) |
| ZA (1) | ZA201401371B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| MX2012010066A (es) | 2010-03-03 | 2012-10-03 | Teva Pharma | Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato. |
| WO2011109526A1 (en) * | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2015038963A1 (en) * | 2013-09-12 | 2015-03-19 | Teva Pharmaceutical Industries, Ltd. | Gene expression biomarkers of laquinimod responsiveness |
| AU2014342917A1 (en) * | 2013-09-27 | 2016-04-21 | Teva Pharmaceutical Industries Ltd. | Laquinimod combination therapy for treatment of multiple sclerosis |
| AU2014348620A1 (en) * | 2013-11-15 | 2016-06-16 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| US20150361757A1 (en) * | 2014-06-17 | 2015-12-17 | Baker Hughes Incoporated | Borehole shut-in system with pressure interrogation for non-penetrated borehole barriers |
| WO2016044103A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| WO2017019862A1 (en) * | 2015-07-30 | 2017-02-02 | Teva Pharmaceuticals Industries Ltd. | Combination formulation of laquinimod and glatiramer acetate with amino acids |
| US20240252461A1 (en) * | 2018-04-13 | 2024-08-01 | Mordechai Chevion | Compositions and methods for treatment of demyelination |
| EP3886858B1 (en) | 2019-12-19 | 2022-05-11 | Active Biotech AB | Compounds for treatment of eye diseases associated with excessive vascularisation |
| KR102350943B1 (ko) * | 2021-07-12 | 2022-01-14 | 주식회사 바움디자인시스템즈 | 집적 회로에 대한 소비 전력을 예측하는 방법 및 이를 수행하는 소비 전력 예측 시스템 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| CA2558380A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| MX2011002033A (es) * | 2008-09-03 | 2011-05-02 | Teva Pharma | 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune. |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| EP2442651B1 (en) * | 2009-06-19 | 2015-07-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| CA2771203C (en) * | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| WO2011056532A2 (en) * | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
-
2012
- 2012-07-27 CN CN201280043755.9A patent/CN103781354A/zh active Pending
- 2012-07-27 SG SG10201606191PA patent/SG10201606191PA/en unknown
- 2012-07-27 EA EA201490377A patent/EA201490377A1/ru unknown
- 2012-07-27 WO PCT/US2012/048684 patent/WO2013016684A1/en not_active Ceased
- 2012-07-27 US US13/560,851 patent/US20130029916A1/en not_active Abandoned
- 2012-07-27 KR KR1020147005638A patent/KR20140054166A/ko not_active Withdrawn
- 2012-07-27 EP EP12817089.1A patent/EP2736335A4/en not_active Withdrawn
- 2012-07-27 PE PE2014000132A patent/PE20142319A1/es not_active Application Discontinuation
- 2012-07-27 AU AU2012286699A patent/AU2012286699A1/en not_active Abandoned
- 2012-07-27 IN IN333MUN2014 patent/IN2014MN00333A/en unknown
- 2012-07-27 JP JP2014523092A patent/JP2014521658A/ja not_active Withdrawn
- 2012-07-27 BR BR112014002095A patent/BR112014002095A2/pt not_active IP Right Cessation
- 2012-07-27 CA CA2843433A patent/CA2843433A1/en not_active Abandoned
- 2012-07-27 HK HK14111812.7A patent/HK1198279A1/xx unknown
- 2012-07-27 CN CN201610302142.2A patent/CN105944081A/zh active Pending
- 2012-07-27 MX MX2014001050A patent/MX2014001050A/es unknown
- 2012-10-01 UY UY0001034358A patent/UY34358A/es not_active Application Discontinuation
-
2014
- 2014-01-28 CL CL2014000209A patent/CL2014000209A1/es unknown
- 2014-02-21 ZA ZA2014/01371A patent/ZA201401371B/en unknown
-
2015
- 2015-07-16 US US14/801,595 patent/US20160038532A1/en not_active Abandoned
-
2016
- 2016-05-06 US US15/148,074 patent/US20160361352A1/en not_active Abandoned
- 2016-07-11 AU AU2016204777A patent/AU2016204777A1/en not_active Abandoned
- 2016-08-24 CL CL2016002132A patent/CL2016002132A1/es unknown
- 2016-11-29 JP JP2016230818A patent/JP2017081930A/ja not_active Withdrawn
- 2016-12-22 HK HK16114575.6A patent/HK1226940A1/zh unknown
-
2017
- 2017-03-27 IL IL251397A patent/IL251397A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11648232B2 (en) | Methods and compositions for treating excessive sleepiness | |
| JP2014530821A5 (enExample) | ||
| JP2010518122A5 (enExample) | ||
| JP2013544887A5 (enExample) | ||
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| JP7069253B2 (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| JP2005510535A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| EP2713724A1 (en) | Methods of treating multiple sclerosis and preserving and/or increasing myelin content | |
| CA2294589A1 (en) | Composition for controlling mood disorders in healthy individuals | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2017510607A5 (enExample) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2010513250A5 (enExample) | ||
| TW202333733A (zh) | 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途 | |
| JP2015522077A5 (enExample) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| CA2859004A1 (en) | Methods and compositions for administration of oxybutynin | |
| CN100518775C (zh) | 一种治疗咳喘的药物组合物及其制剂 | |
| JP2012502105A5 (enExample) | ||
| JP4745661B2 (ja) | 統合失調症治療剤 | |
| CN101677998B (zh) | 包含西洛他唑的治疗精神分裂症药物 | |
| JP2015524460A5 (enExample) | ||
| CN109464441B (zh) | 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用 | |
| JP2016533323A5 (enExample) |